JP2018537519A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537519A5 JP2018537519A5 JP2018536719A JP2018536719A JP2018537519A5 JP 2018537519 A5 JP2018537519 A5 JP 2018537519A5 JP 2018536719 A JP2018536719 A JP 2018536719A JP 2018536719 A JP2018536719 A JP 2018536719A JP 2018537519 A5 JP2018537519 A5 JP 2018537519A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- administered
- inhibitor
- hsp90
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 43
- 231100000419 toxicity Toxicity 0.000 claims description 36
- 230000001988 toxicity Effects 0.000 claims description 36
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 34
- 239000003112 inhibitor Substances 0.000 claims description 23
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 22
- 101710113864 Heat shock protein 90 Proteins 0.000 claims description 20
- 206010025323 Lymphomas Diseases 0.000 claims description 20
- 230000004481 post-translational protein modification Effects 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 12
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical group N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 206010005003 Bladder cancer Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 201000004101 esophageal cancer Diseases 0.000 claims description 8
- 201000003444 follicular lymphoma Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 6
- 239000003207 proteasome inhibitor Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010020843 Hyperthermia Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229940119336 Microtubule stabilizer Drugs 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000000389 T-cell leukemia Diseases 0.000 claims description 4
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 150000003840 hydrochlorides Chemical class 0.000 claims description 4
- 230000036031 hyperthermia Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 229940043355 kinase inhibitor Drugs 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000000527 lymphocytic effect Effects 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 208000025113 myeloid leukemia Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 4
- 230000005855 radiation Effects 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 238000001155 isoelectric focusing Methods 0.000 claims description 3
- 102100039328 Endoplasmin Human genes 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 claims description 2
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 2
- -1 apiocirib Chemical compound 0.000 claims description 2
- 229960001467 bortezomib Drugs 0.000 claims description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 2
- 229960002438 carfilzomib Drugs 0.000 claims description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 2
- 108010021331 carfilzomib Proteins 0.000 claims description 2
- NVGFSTMGRRADRG-IOJSEOPQSA-N chembl553939 Chemical group CS(O)(=O)=O.O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](OC(=O)CN)CC1 NVGFSTMGRRADRG-IOJSEOPQSA-N 0.000 claims description 2
- ZFVRYNYOPQZKDG-MQMHXKEQSA-N chembl560895 Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](O)CC1 ZFVRYNYOPQZKDG-MQMHXKEQSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 108010017007 glucose-regulated proteins Proteins 0.000 claims description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 2
- 229960004942 lenalidomide Drugs 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 2
- 229960005079 pemetrexed Drugs 0.000 claims description 2
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims 6
- 230000002588 toxic effect Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237470P | 2015-10-05 | 2015-10-05 | |
| US62/237,470 | 2015-10-05 | ||
| PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537519A JP2018537519A (ja) | 2018-12-20 |
| JP2018537519A5 true JP2018537519A5 (enExample) | 2019-11-28 |
| JP7132848B2 JP7132848B2 (ja) | 2022-09-07 |
Family
ID=57145064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018536719A Active JP7132848B2 (ja) | 2015-10-05 | 2016-10-05 | 癌の治療のための合理的併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180280397A1 (enExample) |
| EP (1) | EP3359196B1 (enExample) |
| JP (1) | JP7132848B2 (enExample) |
| KR (1) | KR20180058824A (enExample) |
| CN (1) | CN108472376A (enExample) |
| AU (1) | AU2016336351A1 (enExample) |
| BR (1) | BR112018006572A2 (enExample) |
| CA (1) | CA3000851A1 (enExample) |
| EA (1) | EA201890623A1 (enExample) |
| IL (1) | IL258494A (enExample) |
| MA (1) | MA47474A (enExample) |
| MX (1) | MX2018004112A (enExample) |
| TW (1) | TW201722422A (enExample) |
| WO (1) | WO2017062520A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014386214B2 (en) | 2013-12-23 | 2020-05-21 | Memorial Sloan-Kettering Cancer Center | Methods and reagents for radiolabeling |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
| US20240371465A1 (en) * | 2023-05-02 | 2024-11-07 | National Central University | Method, system, and computer readable medium for post-translational modifications detection |
| CN116813622B (zh) * | 2023-05-19 | 2026-02-03 | 中国科学院基础医学与肿瘤研究所(筹) | 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1337275A4 (en) | 2000-11-02 | 2007-05-09 | Sloan Kettering Inst Cancer | METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| NZ598262A (en) | 2009-08-17 | 2014-05-30 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| WO2011044394A1 (en) | 2009-10-07 | 2011-04-14 | Sloan-Kettering Institute For Cancer Research | Purine derivatives useful as hsp90 inhibitors |
| EP2694506B1 (en) | 2011-04-05 | 2017-09-20 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| CA2841069C (en) | 2011-07-08 | 2021-11-23 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| EA201690406A1 (ru) | 2013-08-16 | 2016-08-31 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Селективные ингибиторы grp94 и способы их применения |
| EA201692155A1 (ru) | 2014-05-13 | 2017-04-28 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
-
2016
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko not_active Withdrawn
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en not_active Ceased
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja active Active
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smyth et al. | Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| Jafari et al. | HSP90 and co-chaperones: impact on tumor progression and prospects for molecular-targeted cancer therapy | |
| Singh et al. | Single agent and synergistic activity of the “first-in-class” dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma | |
| Mittal et al. | Recent advances in targeted therapy for glioblastoma | |
| Healy et al. | The importance of Ras in drug resistance in cancer | |
| JP2020531447A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2017530950A5 (enExample) | ||
| Singh et al. | Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib | |
| JP2016533379A5 (enExample) | ||
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2022533578A5 (enExample) | ||
| KR20160066554A (ko) | 브루톤 타이로신 키나제 억제제 및 면역요법을 이용한 치료 | |
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| JP2016528162A5 (enExample) | ||
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| JP2016528246A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| JP2011515397A5 (enExample) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| Zhang et al. | The renewed battle against RAS-mutant cancers | |
| JP2015511226A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний |